Breaking News

Novartis Buys Dendreon Manufacturing Facility

December 20, 2012

IMF facility has PROVENGE manufacturing capabilities

Dendreon Corp. has sold its immunotherapy manufacturing facility (IMF) in Morris Plains, NJ, to Novartis for $43 million in cash. The 173,100-sq.-ft. facility features capabilities to manufacture PROVENGE (sipuleucel-T), Dendreon’s autologous cellular immunotherapy, which received FDA approval for the treatment of metastatic castrate resistant prostate cancer. Earlier this year, Dendreon announced plans to wind down the manufacture of PROVENGE at the facility as part of a strategic restructuring plan.
 
“This agreement represents a positive outcome for Dendreon, our shareholders and New Jersey,” said John H. Johnson, chairman, president and chief executive officer of Dendreon. “Dendreon continues to make progress in improving our financial strength, and this transaction is aligned with that goal as we work to build value for our shareholders. We are also pleased that approximately 100 of the existing employees at the facility will have the opportunity to retain their jobs and work for Novartis as the company builds out its immunotherapy operations and develops new treatments for patients.”

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks